Enteric Disease Testing Market Size, Share, and Industry Analysis 2026-2034

The global Enteric Disease Testing Market is witnessing steady growth as the prevalence of foodborne, waterborne, and gastrointestinal infections continues to rise worldwide. Enteric disease testing plays a critical role in the rapid detection of bacterial, viral, and parasitic pathogens, enabling timely diagnosis, effective treatment, and improved public health surveillance. Increasing investments in molecular diagnostics, laboratory automation, and point-of-care testing technologies are driving market expansion across hospitals, diagnostic laboratories, and healthcare institutions.

According to Fortune Business Insights, the global enteric disease testing market was valued at USD 4.14 billion in 2025 and is projected to grow from USD 4.27 billion in 2026 to USD 5.47 billion by 2034, exhibiting a CAGR of 3.15% during the forecast period.

Why is the Enteric Disease Testing Market Growing?

The increasing incidence of gastrointestinal infections and foodborne illnesses is one of the primary factors driving the Enteric Disease Testing Market. Healthcare providers and public health agencies are increasingly adopting advanced diagnostic technologies to improve pathogen detection, reduce diagnosis time, and strengthen outbreak management.

Growing awareness regarding early disease diagnosis, expanding investments in molecular diagnostics, and increasing adoption of automated laboratory systems are further accelerating market growth. In addition, continuous advancements in multiplex PCR assays, AI-enabled laboratory platforms, and point-of-care diagnostic solutions are creating significant opportunities for manufacturers and healthcare providers.

Enteric disease testing is widely used for:

Foodborne disease diagnosis
Gastrointestinal infection detection
Hospital laboratory testing
Public health surveillance
Clinical diagnostics
Outbreak investigation
Waterborne disease monitoring
Infectious disease management

Growing investments in laboratory modernization and diagnostic innovation continue to create substantial opportunities for market participants.

Key Market Trends Shaping Industry Growth

Rising Adoption of Multiplex Molecular Diagnostics

Healthcare laboratories are increasingly implementing multiplex PCR-based diagnostic systems capable of detecting multiple gastrointestinal pathogens simultaneously with greater accuracy and faster turnaround times.

Growing Demand for Point-of-Care Testing

The increasing need for rapid diagnosis in emergency care, clinics, and remote healthcare settings is driving demand for portable and point-of-care enteric disease testing solutions.

Expansion of Laboratory Automation

Diagnostic laboratories are integrating automated analyzers, artificial intelligence, and cloud-based laboratory information systems to improve workflow efficiency, testing accuracy, and operational productivity.

Increasing Focus on Infectious Disease Surveillance

Governments and healthcare organizations are strengthening disease surveillance programs and investing in advanced diagnostic technologies to improve outbreak detection, antimicrobial resistance monitoring, and public health preparedness.

For detailed market insights: https://www.fortunebusinessinsights.com/enteric-disease-testing-market-116610

Market Segmentation Analysis

Molecular Diagnostics Segment Leads the Market

Based on technique, the Molecular Diagnostics segment accounted for the largest market share in 2025 due to its high sensitivity, rapid turnaround time, and ability to simultaneously detect multiple bacterial, viral, and parasitic pathogens.

Hospital Laboratories Segment Dominates Market Demand

Based on end user, the Hospital Laboratories segment held the largest market share owing to increasing patient admissions, rising diagnostic testing volumes, and widespread availability of advanced laboratory infrastructure for infectious disease diagnosis.

Regional Insights

North America Leads the Global Market

North America accounted for the largest share of the global Enteric Disease Testing Market in 2025. Advanced healthcare infrastructure, increasing investments in molecular diagnostics, and strong public health surveillance programs continue to drive regional market growth. The United States remains the largest contributor to regional revenue.

Asia Pacific Witnesses Strong Growth

Asia Pacific is expected to register significant growth during the forecast period due to expanding healthcare infrastructure, increasing awareness of foodborne diseases, rising healthcare investments, and growing adoption of advanced diagnostic technologies. China, India, and Japan remain key regional growth markets.

Europe Maintains Strong Market Position

Europe continues to witness healthy market growth supported by increasing investments in infectious disease diagnostics, expanding laboratory modernization initiatives, and growing adoption of molecular testing technologies. Germany, the United Kingdom, and France remain important regional markets.

Competitive Landscape

The global Enteric Disease Testing Market is highly competitive, with leading diagnostic companies focusing on molecular testing technologies, rapid diagnostic solutions, laboratory automation, and multiplex assay development. Companies are investing in advanced PCR platforms, immunoassays, next-generation diagnostic systems, and AI-enabled laboratory solutions to improve testing accuracy, reduce turnaround time, and enhance infectious disease detection.

The increasing demand for early diagnosis of foodborne and waterborne infections, along with rising investments in public health surveillance and laboratory modernization, is encouraging manufacturers to expand their product portfolios and strengthen their global presence. Strategic collaborations, mergers, acquisitions, and research partnerships continue to enhance market competitiveness.

Major Companies Operating in the Enteric Disease Testing Market

Thermo Fisher Scientific Inc.
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
bioMérieux SA
QIAGEN N.V.
Danaher Corporation (Cepheid)
BD (Becton, Dickinson and Company)
Bio-Rad Laboratories, Inc.
Meridian Bioscience, Inc.
Seegene Inc.

These companies continue to strengthen their market position through innovative product launches, strategic collaborations, laboratory automation, and expansion of molecular diagnostic solutions.

Recent Industry Developments

Leading manufacturers are introducing multiplex molecular diagnostic panels capable of detecting multiple gastrointestinal pathogens from a single patient sample.
Companies are investing in rapid PCR-based diagnostic platforms that provide faster and more accurate results for hospitals and clinical laboratories.
Growing adoption of point-of-care testing solutions is improving access to enteric disease diagnosis in emergency departments, clinics, and remote healthcare settings.
Diagnostic companies are integrating artificial intelligence (AI), cloud-based reporting, and automated laboratory workflows to improve operational efficiency and clinical decision-making.
Strategic collaborations between healthcare organizations, research institutes, and diagnostic companies continue to accelerate innovation in infectious disease testing technologies.

Future Outlook

The future of the Enteric Disease Testing Market appears promising as the global burden of foodborne and waterborne diseases continues to increase. Rising awareness of early diagnosis, stronger public health surveillance programs, and increasing investments in advanced laboratory infrastructure are expected to support sustained market growth throughout the forecast period.

Technological advancements in molecular diagnostics, multiplex PCR, laboratory automation, artificial intelligence, and digital healthcare platforms are expected to improve testing speed, analytical accuracy, and workflow efficiency. These innovations will enable healthcare providers to diagnose infectious diseases more effectively while improving patient outcomes and outbreak management.

Emerging economies are expected to create significant growth opportunities due to expanding healthcare infrastructure, increasing government investments in infectious disease control, and growing adoption of modern diagnostic technologies. Companies that prioritize innovation, automation, and high-performance molecular diagnostics are likely to strengthen their competitive position over the coming years.

Request Sample Report

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/enteric-disease-testing-market-116610

ABOUT

Fortune Business Insights™ provides strategic corporate analysis and comprehensive market intelligence that helps organizations make informed business decisions. Our reports combine in-depth market research with reliable industry data prepared by experienced analysts and consultants using advanced research methodologies. These insights enable businesses to identify emerging opportunities, evaluate competitive dynamics, and formulate effective long-term growth strategies across diverse industries.